BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Liraglutide (Saxenda) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Liraglutide (Saxenda)\, from ClinicalTria
 ls.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07225816-11053@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20261213
DTEND;VALUE=DATE:20261214
SUMMARY:Liraglutide (Saxenda): Phase 1 readout est. (NCT07225816)
DESCRIPTION:Liraglutide (Saxenda)\, phase 1\, Obesity.\nStudy: Examination 
 of How the Duration of Fasting and Temporary Stopping of GLP-1 Medications
  Affect the Amount of Food Left in the Stomach in People Using Liraglutide
  (Injected)\, Semaglutide (Taken by Mouth) or Semaglutide (Injected)\nEsti
 mated primary completion: 13 December 2026. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/liraglutide-saxenda#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT07225816
URL:https://assetmemo.bio/drug/liraglutide-saxenda#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06865365-11053@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20270201
DTEND;VALUE=DATE:20270202
SUMMARY:Liraglutide (Saxenda): Phase 4 readout est. (NCT06865365)
DESCRIPTION:Liraglutide (Saxenda)\, phase 4\, Obesity.\nStudy: Preoperative
  Use of Liraglutide Additionally to Common Dietological Measures as Oppose
 d to Dietological Measures Alone\nEstimated primary completion: 1 February
  2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/liraglutide-sa
 xenda#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT06865365
URL:https://assetmemo.bio/drug/liraglutide-saxenda#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07590219-11053@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Liraglutide (Saxenda): Phase 4 readout est. (NCT07590219)
DESCRIPTION:Liraglutide (Saxenda)\, phase 4\, Obesity.\nStudy: Use of Lirag
 lutide in Children Aged 6 to 12 Years With Severe Obesity\nEstimated prima
 ry completion: April 2027. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/liraglutide-saxenda#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT07590219
URL:https://assetmemo.bio/drug/liraglutide-saxenda#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02944500-11053@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Liraglutide (Saxenda): Phase 4 readout est. (NCT02944500)
DESCRIPTION:Liraglutide (Saxenda)\, phase 4\, Obesity.\nStudy: Saxenda: Und
 erlying Mechanisms and Clinical Outcomes\nEstimated primary completion: Ju
 ne 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/liraglutide-
 saxenda#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT02944500
URL:https://assetmemo.bio/drug/liraglutide-saxenda#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07301437-11053@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Liraglutide (Saxenda): Phase 4 readout est. (NCT07301437)
DESCRIPTION:Liraglutide (Saxenda)\, phase 4\, Obesity.\nStudy: RWS of of Li
 raglutide Alone and in Combination With Orlistat for Weight Loss in Overwe
 ight/Obese Patients.\nEstimated primary completion: 31 August 2027. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/liraglutide-saxenda#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT07301437
URL:https://assetmemo.bio/drug/liraglutide-saxenda#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06742710-11053@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20290530
DTEND;VALUE=DATE:20290531
SUMMARY:Liraglutide (Saxenda): Phase 4 readout est. (NCT06742710)
DESCRIPTION:Liraglutide (Saxenda)\, phase 4\, Obesity.\nStudy: Liraglutide 
 Treatment in Obese Infertile PCOS Women\nEstimated primary completion: 30 
 May 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/liraglutide
 -saxenda#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT06742710
URL:https://assetmemo.bio/drug/liraglutide-saxenda#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
